research use only

Suramin sodium salt phosphatase inhibitor

Cat.No.S8942

Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatase (PTPases) inhibitor, also is the potent inhibitor of sirtuins, purified topoisomerase II and SARS-CoV-2 RNA-dependent RNA polymerase (RdRp).
Jump to

Quality Control

Batch: S894201 DMSO]100 mg/mL]false]Water]100 mg/mL]false]Ethanol]Insoluble]false Purity: 99.87%
99.87

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (69.67 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 100 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 1435.23 Formula

C51H40N6O23S6.6Na

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 129-46-4 -- Storage of Stock Solutions

Synonyms Suramin hexasodium salt SMILES CC1=C(C=C(C=C1)C(=O)NC2=C3C(=CC(=CC3=C(C=C2)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-])NC(=O)C4=CC(=CC=C4)NC(=O)NC5=CC=CC(=C5)C(=O)NC6=C(C=CC(=C6)C(=O)NC7=C8C(=CC(=CC8=C(C=C7)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-])C.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
Yersinia PTPase
Yersinia PTP1B
RdRp
(in solution based assays)
0.26 μM
SirT1
(in the a fluorescent deacetylase assay)
297 nM
SirT2
(in the a fluorescent deacetylase assay)
1.15 μM
Topoisomerase II
(in either decatenation or relaxation assays)
5 μM
SirT5
(in the a fluorescent deacetylase assay)
22 μM
References
  • [4] https://pubmed.ncbi.nlm.nih.gov/33674802/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-30)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06866275 RECRUITING
Autism Spectrum Disorder (ASD)
Children's Hospital of Orange County
2025-04-09 PHASE2
NCT04496596 UNKNOWN
Acute Kidney Injury
Rediscovery Life Sciences
2020-11-13 PHASE2
NCT06058962 COMPLETED
Autism Spectrum Disorder
Paxmedica
2019-06-01 PHASE2
NCT03804749 UNKNOWN
Hand, Foot and Mouth Disease
First Affiliated Hospital of Zhejiang University
2018-12-19 PHASE1
NCT02508259 COMPLETED
Autism Spectrum Disorders
University of California, San Diego
2015-05 PHASE1; PHASE2
NCT01671332 COMPLETED
Carcinoma, Non Small Cell Lung
University of Wisconsin, Madison
2012-06 PHASE2

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.